Invention Grant
- Patent Title: Peptides having specificity for the lungs
-
Application No.: US14911197Application Date: 2014-08-06
-
Publication No.: US10688151B2Publication Date: 2020-06-23
- Inventor: Martin Trepel , Jakob Koerbelin , Stefan Michelfelder
- Applicant: Boehringer Ingelheim International GmbH
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agency: Hovey Williams LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@40bf2082
- International Application: PCT/EP2014/066892 WO 20140806
- International Announcement: WO2015/018860 WO 20150212
- Main IPC: A61K38/08
- IPC: A61K38/08 ; C12N15/00 ; C12N5/02 ; C12N5/07 ; A61K38/04 ; C07K5/00 ; C07K7/00 ; C07K16/00 ; C07K17/00 ; C07H21/02 ; A61K38/16 ; C12N15/86 ; C07K14/005 ; C12N7/00

Abstract:
The invention relates to a peptide, polypeptide, or protein that binds specifically to cells of the lung endothelium. The peptide, polypeptide, or protein can be a component of a viral capsid and can be used to lead a recombinant viral vector selectively to the lung endothelial tissue after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention thus further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid comprising the peptide, polypeptide, or protein according to the invention and which comprises at least one transgene packaged in the capsid. The viral vector is suitable in particular for the therapeutic treatment of a lung disorder or a lung disease. The invention further relates to cells and pharmaceutical compositions which comprise the viral vector according to the invention.
Public/Granted literature
- US20160175389A1 NEW PEPTIDES HAVING SPECIFICITY FOR THE LUNGS Public/Granted day:2016-06-23
Information query
IPC分类: